Heparan Sulfated Glypican-4 Is Released from Astrocytes by Proteolytic Shedding and GPI- Anchor Cleavage Mechanisms

Total Page:16

File Type:pdf, Size:1020Kb

Heparan Sulfated Glypican-4 Is Released from Astrocytes by Proteolytic Shedding and GPI- Anchor Cleavage Mechanisms Research Article: New Research | Development Heparan sulfated Glypican-4 is released from astrocytes by proteolytic shedding and GPI- anchor cleavage mechanisms https://doi.org/10.1523/ENEURO.0069-21.2021 Cite as: eNeuro 2021; 10.1523/ENEURO.0069-21.2021 Received: 17 February 2021 Revised: 9 July 2021 Accepted: 15 July 2021 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2021 Huang and Park This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. 1 1. Manuscript Title: Heparan sulfated Glypican-4 is released from astrocytes by proteolytic 2 shedding and GPI-anchor cleavage mechanisms 3 4 2. Abbreviated Title: GPC4 is released from astrocytes largely by proteolytic shedding 5 6 3. Authors: 7 Kevin Huang1, 2, Sungjin Park1 8 1 University of Utah School of Medicine, Department of Neurobiology, Salt Lake City, UT 84112 9 2 University of Utah, Interdepartmental Program in Neuroscience, Salt Lake City, UT 84112 10 11 4. Author Contributions: KH and SP designed research; KH performed research; KH and SP 12 analyzed data; KH and SP wrote the paper. 13 14 5. Correspondence should be addressed to: 15 Sungjin Park, PhD 16 Department of Neurobiology and Anatomy, University of Utah School of Medicine, Salt Lake 17 City, UT 84112, USA. Tel: +1-801-581-6106 18 E-mail: [email protected] 19 20 6. Number of Figures: 7 2410. Number of words for Significance 21 7. Number of Tables: 2 25Statement: 98 22 8. Number of Multimedia: 0 2611. Number of words for Introduction: 705 23 9. Number of words for Abstract: 168 2712. Number of words for Discussion: 1,212 28 29 13. Acknowledgements: We thank Joosang Park for maintaining the mouse colony and 30 experimental assistance; Williams, Shepherd, Sundquist labs for materials, equipment, and 31 advice; U of U Core facilities. 32 33 14. Conflict of Interest: Authors report no conflict of interest 34 35 15. Funding Sources: This work was supported by NIH grant R01NS102444 to S.P. 36 1 37 Abstract 38 Astrocytes provide neurons with diffusible factors that promote synapse formation and 39 maturation. In particular, glypican-4/GPC4 released from astrocytes promotes the maturation of 40 excitatory synapses. Unlike other secreted factors, GPC4 contains the C-terminal GPI- 41 anchorage signal. However, the mechanism by which membrane-tethered GPC4 is released 42 from astrocytes is unknown. Using mouse primary astrocyte cultures and a quantitative 43 luciferase-based release assay, we show that GPC4 is expressed on the astrocyte surface via a 44 GPI-anchorage. Soluble GPC4 is robustly released from the astrocytes largely by proteolytic 45 shedding and, to a lesser extent, by GPI-anchor cleavage, but not by vesicular release. 46 Pharmacological, overexpression, and loss of function screens showed that ADAM9 in part 47 mediates the release of GPC4 from astrocytes. The released GPC4 contains the heparan 48 sulfate side chain, suggesting that these release mechanisms provide the active form that 49 promotes synapse maturation and function. Overall, our studies identified the release 50 mechanisms and the major releasing enzyme of GPC4 in astrocytes and will provide insights 51 into understanding how astrocytes regulate synapse formation and maturation. 2 52 Significance Statement 53 Astrocyte-derived diffusible factors regulate synapse development and function. However, the 54 regulatory mechanism underlying the release of astrocyte-derived factors is poorly understood. 55 Noting that, unlike many other secreted factors, glypican-4/GPC4 is GPI-anchored, we 56 characterized the release mechanism of GPI-anchored GPC4 from astrocytes and identified the 57 releasing enzyme. Heparan sulfated GPC4 is robustly released from the astrocytes largely by 58 proteolytic shedding. In particular, ADAM9 in part mediates the release of GPC4 from 59 astrocytes. Our study provides an enzymatic mechanism for releasing GPC4 from astrocytes 60 and will provide a novel opportunity to understand the regulatory mechanism of neuron-glia 61 communication for synaptogenesis. 3 62 Introduction 63 Surface shedding is a mechanism by which specific surface proteins are cleaved and an 64 ectodomain is released into the extracellular space. The shedding or release of surface proteins 65 have been found to play important roles in various biological functions (Lichtenthaler et al., 66 2018) . Ectodomain shedding can act to stop activity of proteins at the membrane, such as 67 removing cell surface receptors or cell adhesion proteins, as in the case of N-cadherin (Reiss et 68 al., 2005). Alternatively, shedding can release an active protein from the cell surface to act as a 69 long range, diffusible signaling factor such as syndecan-1 in FGF-2 activation during wound 70 healing (Kato et al., 1998). In this context, shedding can allow for temporally and spatially 71 regulated release or activity of a biomolecule. In other cases, shedding acts as a molecular 72 switch, changing the signaling function of the protein from one role while anchored to the 73 surface membrane to another when shed. For example, membrane-anchored TNF- can 74 activate TNFR2 upon direct cell to cell contact to activate anti-inflammatory pathways, however 75 when shed, TNF- acts as a paracrine signal to drive proinflammatory TNFR1 signaling (Grell et 76 al., 1995). In other cases, released proteins can change the signaling functions of related 77 receptor complexes, such as when released soluble CNTFR converts the LIF receptor 78 complex and transduces CNTF signaling in the cells that are not normally responsive to CNTF 79 (Davis et al., 1993). 80 The release of surface proteins also been shown to play important roles in synapse 81 development (Lichtenthaler et al., 2018). For example, Nogo-66 receptor ectodomain shedding 82 drives excitatory synapse formation in vivo (Sanz et al., 2018). Proteolytic shedding of cell 83 adhesion molecules causes the structural and functional modifications of synapses (Bajor and 84 Kaczmarek, 2013; Nagappan-Chettiar et al., 2017). Glypican-4/GPC4 has been identified as a 85 cell surface protein sufficient to drive neuronal synaptogenesis in vitro (Allen et al., 2012). GPC4 86 is a GPI-anchored protein (Filmus et al., 2008) and highly expressed in astrocytes (Cahoy et al., 4 87 2008; Zhang et al., 2014). Notably, GPC4 expressed in astrocytes are released from the cell 88 and the released GPC4 facilitates synapse maturation in vitro (Allen et al., 2012). While GPC4’s 89 downstream mechanism of action of signaling through RPTPs been characterized (Farhy- 90 Tselnicker et al., 2017), little is known about how GPC4 is shed or released from astrocytes. A 91 better understanding of the release mechanism of GPC4 offers insights into the synaptogenic 92 role of astrocytes in neuronal development and could lead to novel therapeutic targets for 93 synaptopathic disorders such as autism, schizophrenia, Down syndrome, and epilepsy (Dowling 94 and Allen, 2018; Wilson and Newell-Litwa, 2018). 95 GPI-anchored proteins can be released from the producing cells via multiple 96 mechanisms, which include proteolytic shedding, GPI-anchor cleavage, and vesicular release 97 (Muller, 2018). There are GPI-anchored proteins which are shed through proteolytic 98 mechanisms such as metalloprotease-mediated shedding of Prion protein and UL16 binding 99 proteins, MHC class I-related molecules (Fernandez-Messina et al., 2010; Linsenmeier et al., 100 2018). GPI-anchored proteins can also be shed though a lipase-based cleavage mechanism 101 (Park et al., 2013; van Veen et al., 2017). In this context, unlike proteolytic shedding which 102 releases an ectodomain fragment, an entire protein is released from the cell. GPI-anchored 103 proteins have also been shown to associate with a vesicular membrane or lipid particle while 104 becoming separated from the cell (Muller, 2018). 105 The mechanism by which GPC4 is released has implications to the role GPC4 plays in 106 downstream signaling. GPC4 is post-translationally modified with heparan sulfate side chains at 107 residues near the C-terminus of the protein. These heparan sulfate side chains are necessary 108 for the known synaptogenic signaling functions of GPC4 (Allen et al., 2012; Condomitti et al., 109 2018). Thus, identification of the released form of GPC4 is critical to understand how astrocyte- 110 derived GPC4 regulates synaptogenesis. 111 Here, we show that GPC4 is released from the cell surface of astrocytes in vitro. We 112 observed that GPC4 is released predominantly via proteolytic shedding, and to a lesser extent 5 113 by GPI-anchor cleavage, but not by vesicular release. The released GPC4 contains heparan 114 sulfate attachment, suggesting that both release mechanisms preserve the synaptogenic activity 115 of GPC4 in the extracellular space. We also identify ADAM9 as a proteolytic sheddase for 116 GPC4. Overall, these observations show that astrocytes release heparan sulfate containing 117 GPC4 by multiple mechanisms. 118 119 Materials and Methods: 120 Animals 121 All animal care and experiments were conducted in accordance with NIH guidelines and 122 the IACUC committee of the University of Utah (protocol no. 21-02004). C57Bl6/J mouse lines 123 were maintained under the normal housing conditions with food and water available ad libitum 124 and 12h light/dark cycle in a dedicated facility. All primary astrocyte cultures were generated 125 using neonatal wild-type mice of either sex. 126 Statistical Analyses 127 Statistics were performed using Graphpad Prism software version 9.
Recommended publications
  • Multiple Antibodies Identify Glypican-1 Associated with Exosomes from Pancreatic
    bioRxiv preprint doi: https://doi.org/10.1101/145706; this version posted July 6, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Multiple antibodies identify glypican-1 associated with exosomes from pancreatic cancer cells and serum from patients with pancreatic cancer Chengyan Dong1*, Li Huang1*, Sonia A. Melo2,3,4, Paul Kurywchak1, Qian Peng1, Christoph Kahlert5, Valerie LeBleu1# & Raghu Kalluri1# 1Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX 77005 2Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal (iI3S), 4200 Porto, Portugal; 3Institute of Pathology and Molecular Immunology of the University of Porto (IPATIMUP), 4200 Porto, Portugal; 4Medical School, Porto University (FMUP), 4200 Porto, Portugal 5 Department of Gastrointestinal, Thoracic and Vascular Surgery, Technische Universität Dresden, Germany * co-first authors # co-corresponding authors Exosomes are man-sized vesicles shed by all cells, including cancer cells. Exosomes can serve as novel liquid biopsies for diagnosis of cancer with potential prognostic value. The exact mechanism/s associated with sorting or enrichment of cellular components into exosomes are still largely unknown. We reported Glypican-1 (GPC1) on the surface of cancer exosomes and provided evidence for the enrichment of GPC1 in exosomes from patients with pancreatic cancer1. Several different laboratories have validated this novel conceptual advance and reproduced the original experiments using multiple antibodies from different sources. These include anti-GPC1 antibodies from ThermoFisher (PA5- 28055 and PA-5-24972)1,2, Sigma (SAB270028), Abnova (MAB8351, monoclonal antibodies clone E9E)3, EMD Millipore (MAB2600-monoclonal antibodies)4, SantaCruz5, and R&D Systems (BAF4519)2.
    [Show full text]
  • Derived Cytotoxic T-Lymphocyte Epitope Peptide
    INTERNATIONAL JOURNAL OF ONCOLOGY 42: 831-838, 2013 Identification of an H2-Kb or H2-Db restricted and glypican-3- derived cytotoxic T-lymphocyte epitope peptide TATSUAKI IWAMA1,2, KAZUTAKA HORIE1, TOSHIAKI YOSHIKAWA1, DAISUKE NOBUOKA1, MANAMI SHIMOMURA1, YU SAWADA1 and TETSUYA NAKATSURA1,2 1Division of Cancer Immunotherapy, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577; 2Research Institute for Biomedical Sciences, Tokyo University of Science, Japan Received November 15, 2012; Accepted December 28, 2012 DOI: 10.3892/ijo.2013.1793 Abstract. Glypican-3 (GPC3) is overexpressed in human cholangiocarcinoma (ICC), with HCC as the most common. hepatocellular carcinoma (HCC) but not expressed in normal Regarding HCC therapy, hepatectomy, percutaneous local tissues except for placenta and fetal liver and therefore is an therapy and transcatheter arterial embolization (TAE) are ideal target for cancer immunotherapy. In this study, we common, but the recurrence rate with conventional therapies for identified an H2-Kb or H2-Db restricted and murine GPC3 advanced HCC patients is still high (2). Therefore, developing a (mGPC3)-derived cytotoxic T-lymphocyte (CTL) epitope novel curative therapy or an effective adjuvant therapy for HCC peptide in C57BL/6 (B6) mice, which can be used in the design is important. of preclinical studies of various therapies with GPC3-target Recently, immunotherapy, which consists of a peptide immunotherapy in vivo. First, 11 types of 9- to 10-mer peptides vaccine, protein vaccine, or DNA vaccine, has become a predicted to bind with H2-Kb or H2-Db were selected from the potentially promising option for HCC (3,4).
    [Show full text]
  • Supplementary Material Contents
    Supplementary Material Contents Immune modulating proteins identified from exosomal samples.....................................................................2 Figure S1: Overlap between exosomal and soluble proteomes.................................................................................... 4 Bacterial strains:..............................................................................................................................................4 Figure S2: Variability between subjects of effects of exosomes on BL21-lux growth.................................................... 5 Figure S3: Early effects of exosomes on growth of BL21 E. coli .................................................................................... 5 Figure S4: Exosomal Lysis............................................................................................................................................ 6 Figure S5: Effect of pH on exosomal action.................................................................................................................. 7 Figure S6: Effect of exosomes on growth of UPEC (pH = 6.5) suspended in exosome-depleted urine supernatant ....... 8 Effective exosomal concentration....................................................................................................................8 Figure S7: Sample constitution for luminometry experiments..................................................................................... 8 Figure S8: Determining effective concentration .........................................................................................................
    [Show full text]
  • A Krasg12d-Driven Genetic Mouse Model of Pancreatic Cancer Requires Glypican-1 for Efficient Proliferation and Angiogenesis
    Oncogene (2012) 31, 2535–2544 & 2012 Macmillan Publishers Limited All rights reserved 0950-9232/12 www.nature.com/onc ORIGINAL ARTICLE A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis CA Whipple1,2, AL Young1,2 and M Korc1,2 1Departments of Medicine and Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH, USA and 2The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA Pancreatic ductal adenocarcinomas (PDACs) exhibit Introduction multiple molecular alterations and overexpress heparin- binding growth factors (HBGFs) and glypican-1 (GPC1), Pancreatic ductal adenocarcinoma (PDAC) is a highly a heparan sulfate proteoglycan that promotes efficient metastatic malignancy that is the fourth leading cause signaling by HBGFs. It is not known, however, whether of cancer death in the United States, with an overall GPC1 has a role in genetic mouse models of PDAC. 5-year survival rate of o6% (Siegel et al., 2011). PDAC Therefore, we generated a GPC1 null mouse that exhibits a wide range of genetic and epigenetic altera- combines pancreas-specific Cre-mediated activation of tions including a high frequency (90–95%) of activating oncogenic Kras (KrasG12D) with deletion of a conditional Kras mutations, homozygous deletion (85%) and INK4A/Arf allele (Pdx1-Cre;LSL-KrasG12D;INK4A/ epigenetic silencing (15%) of the tumor suppressor Arflox/lox;GPC1À/À mice). By comparison with Pdx1- genes p16INK4A/p14ARF (INK4A), as well as an over- Cre;LSL-KrasG12D;INK4A/Arflox/lox mice that were wild abundance of heparin-binding growth factors (HBGFs) type for GPC1, the Pdx1-Cre;LSL-KrasG12D;INK4A/ (Korc, 2003; Schneider and Schmid, 2003).
    [Show full text]
  • Is Osteopontin a Friend Or Foe of Cell Apoptosis in Inflammatory
    International Journal of Molecular Sciences Review Is Osteopontin a Friend or Foe of Cell Apoptosis in Inflammatory Gastrointestinal and Liver Diseases? Tomoya Iida ID , Kohei Wagatsuma, Daisuke Hirayama and Hiroshi Nakase * Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Minami 1-jo Nishi 16-chome, Chuo-ku, Sapporo 060-8543, Japan; [email protected] (T.I.); [email protected] (K.W.); [email protected] (D.H.) * Correspondence: [email protected]; Tel.: +81-11-611-2111; Fax: +81-11-611-2282 Received: 22 November 2017; Accepted: 19 December 2017; Published: 21 December 2017 Abstract: Osteopontin (OPN) is involved in a variety of biological processes, including bone remodeling, innate immunity, acute and chronic inflammation, and cancer. The expression of OPN occurs in various tissues and cells, including intestinal epithelial cells and immune cells such as macrophages, dendritic cells, and T lymphocytes. OPN plays an important role in the efficient development of T helper 1 immune responses and cell survival by inhibiting apoptosis. The association of OPN with apoptosis has been investigated. In this review, we described the role of OPN in inflammatory gastrointestinal and liver diseases, focusing on the association of OPN with apoptosis. OPN changes its association with apoptosis depending on the type of disease and the phase of disease activity, acting as a promoter or a suppressor of inflammation and inflammatory carcinogenesis. It is essential that the roles of OPN in those diseases are elucidated, and treatments based on its mechanism are developed. Keywords: osteopontin; apoptosis; gastrointestinal; liver; inflammation; cacinogenesis 1. Introduction Cancer epidemiologists have described three carcinogenesis factors: daily diet, smoking, and inflammation [1].
    [Show full text]
  • Correlation of Glypican-1 Expression with TGF-ß, BMP, and Activin Receptors in Pancreatic Ductal Adenocarcinoma
    1139-1148 3/10/06 15:55 Page 1139 INTERNATIONAL JOURNAL OF ONCOLOGY 29: 1139-1148, 2006 Correlation of glypican-1 expression with TGF-ß, BMP, and activin receptors in pancreatic ductal adenocarcinoma HANY KAYED1, JÖRG KLEEFF1, SHEREEN KELEG1, XIAOHUA JIANG1, ROLAND PENZEL2, THOMAS GIESE3, HANSWALTER ZENTGRAF4, MARKUS W. BÜCHLER1, MURRAY KORC5 and HELMUT FRIESS1 1Department of General Surgery, Institutes of 2Pathology and 3Immunology, University of Heidelberg; 4Department of Applied Tumor Virology, German Cancer Research Center, Heidelberg, Germany; 5Departments of Medicine, Pharmacology and Toxicology, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH 03756, USA Received March 23, 2006; Accepted May 29, 2006 Abstract. Glypican1 (GPC1) is a cell surface heparan sulfate induction and Smad2 phosphorylation. In conclusion, enhanced proteoglycan that acts as a co-receptor for heparin-binding GPC1 expression correlates with BMP and activin receptors growth factors as well as for members of the TGF-ß family. in pancreatic cancer. GPC1 down-regulation suppresses GPC1 plays a role in pancreatic cancer by regulating growth pancreatic cancer cell growth and slightly modifies signaling factor responsiveness. In view of the importance of members of members of the TGF-ß family of growth factors. of the TGF-ß family in pancreatic cancer, in the present study, the role of GPC1 in TGF-ß, BMP and activin signaling was Introduction analyzed. Quantitative RT-PCR and immunohistochemistry were utilized to analyze GPC1 and TGF-ß, BMP and activin Glypican1 (GPC1) is a member of the family of heparan sulfate receptor expression levels. Panc-1 and T3M4 pancreatic cancer proteoglycans (HSPG), which are ubiquitous proteins that cells were transfected in a stable manner with a GPC1 antisense are attached to the extracytoplasmic surface of the cell expression construct.
    [Show full text]
  • Papillomavirus Binding and Entry
    PAPILLOMAVIRUS BINDING AND ENTRY The heparan sulfate receptor and inhibition by lactoferrin by Peter Drobni Department of Clinical Microbiology, Virology Umeå University, Sweden 2005 Front cover: Binding of papillomavirus to glycoseaminoglycans. Aquarelle by Mirva Drobni © 2005 Peter Drobni Printed in Sweden by Solfjädern Offset AB Umeå 2005 tom tom Till Elliot & Mirva TABLE OF CONTENTS 1. Abstract 9 2. List of papers 10 3. Abbreviations 11 4. Sammanfattning 12 5. Summary of papers 14 5.1 Paper I 14 5.2 Paper II 14 5.3 Paper III 15 5.4 Paper IV 15 6. Introduction 17 6.1 Human papillomavirus (HPV) 17 6.1.1 HPV History 17 6.1.2 Phylogeny 18 6.1.3 Genome organization 19 6.1.4 Structure 19 6.1.5 Life cycle 21 6.1.6 VLPs as research tools 22 6.1.7 Receptors for human papillomaviruses 23 6.1.8 Internalization 23 6.1.9 PV proteins 24 6.1.10 Disease 27 6.1.11 Therapy 29 6.1.12 Immune response 31 6.1.13 Vaccines 33 7 6.2 Glycosaminoglycans 35 6.2.1 General 35 6.2.2 As viral receptors 36 6.3 Lactoferrin 36 6.3.1 Structure 37 6.3.2 Antiviral mechanism 38 6.3.3 Lactoferricin 38 7. Aim of the thesis 39 8. Materials and methods 40 8.1 Cell lines 40 8.2 VLP production 40 8.3 CFDA-SE labeling 40 8.4 Binding assays 41 8.5 Internalization assays 41 9. Results and discussion 42 9.1 As a tool to study infection 42 9.2 CFDA-SE as an internalization assay 42 9.3 Heparan sulfate as an HPV receptor 43 9.4 Lactoferrin and lactoferricin as HPV inhibitors 44 9.5 Results from paper I 46 9.6 Results from paper II 46 9.7 Results from paper III 47 9.8 Results from paper IV 48 10.
    [Show full text]
  • Up-Regulation of Glypican-3 in Human Hepatocellular Carcinoma
    ANTICANCER RESEARCH 30: 5055-5062 (2010) Up-regulation of Glypican-3 in Human Hepatocellular Carcinoma MASAHIRO SUZUKI1, KAZUSHI SUGIMOTO1, JUNICHIRO TANAKA1, MASAHIKO TAMEDA1, YUJI INAGAKI1, SATOKO KUSAGAWA1, KEIICHIRO NOJIRI1, TETSUYA BEPPU1, KENTARO YONEDA1, NORIHIKO YAMAMOTO1, MASAAKI ITO1, MISAO YONEDA2, KAZUHIKO UCHIDA3, KOUJIRO TAKASE1 and KATSUYA SHIRAKI1 1Department of Internal Medicine, and 2Department of Pathology, Mie Graduate University School of Medicine, Tsu, Mie 514-8507, Japan; 3Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-0006, Japan Abstract. Aim: To investigate the expression and chronic liver disease and HCC found that serum GPC3 significance of glypican-3 (GPC3) in human hepatocellular protein levels were significantly elevated in the latter. carcinoma (HCC). Materials and Methods: DNA chips were Conclusion: GPC3 is highly expressed in HCC, and its used to measure the expression of mRNAs for members of the expression pattern differs according to the degree of cell glypican and syndecan families of heparan sulfate differentiation. In addition, the expression of GPC3 is proteoglycans (HSPGs) in normal liver tissue, non-tumor regulated by Janus kinase-STAT signaling. GPC3 shows tissues and HCC. GPC3 protein expression was investigated potential as a tumor biomarker for HCC that can be used for by immunohistochemical staining in the tissues samples and molecularly targeted therapy. Western blotting in human HCC cell lines. In addition, the levels of GPC3 protein in the blood were determined by Hepatocellular carcinoma (HCC) is one of the most common ELISA. Results: Only the expression of GPC3 was found to carcinomas worldwide. The prognosis of HCC is generally be markedly elevated in HCCs.
    [Show full text]
  • Therapeutically Targeting Glypican-2 Via Single-Domain Antibody-Based
    Therapeutically targeting glypican-2 via single-domain PNAS PLUS antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma Nan Lia, Haiying Fua,b, Stephen M. Hewittc, Dimiter S. Dimitrovd, and Mitchell Hoa,1 aLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; bDepartment of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China; cLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; and dCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702 Edited by Dennis A. Carson, University of California, San Diego, La Jolla, CA, and approved July 3, 2017 (received for review April 11, 2017) Neuroblastoma is a childhood cancer that is fatal in almost half of in the nervous system (7). It is known to participate in cellular patients despite intense multimodality treatment. This cancer is adhesion and is thought to regulate the growth and guidance of derived from neuroendocrine tissue located in the sympathetic axons (8). The role of GPC2 in the pathogenesis of neuroblastoma nervous system. Glypican-2 (GPC2) is a cell surface heparan sulfate or any other cancers has not been reported. proteoglycan that is important for neuronal cell adhesion and The Wnt/β-catenin signaling pathway is highly conserved and neurite outgrowth. In this study, we find that GPC2 protein is highly plays an essential role in various processes of embryonic devel- expressed in about half of neuroblastoma cases and that high opment (9). Additionally, it has been linked to pathogenesis of GPC2 expression correlates with poor overall survival compared numerous adult and pediatric tumors (10).
    [Show full text]
  • CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing
    Published OnlineFirst April 12, 2017; DOI: 10.1158/0008-5472.CAN-16-3351 Cancer Molecular and Cellular Pathobiology Research CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma Toyoki Yoshimoto1,2, Miwa Tanaka1, Mizuki Homme1, Yukari Yamazaki1, Yutaka Takazawa3, Cristina R. Antonescu4, and Takuro Nakamura1 Abstract CIC-DUX4 sarcoma (CDS) or CIC-rearranged sarcoma is a short spindle cells. Gene-expression profiles of CDS and eMC subcategory of small round cell sarcoma resembling the morpho- revealed upregulation of CIC-DUX4 downstream genes such as logical phenotypes of Ewing sarcoma (ES). However, recent PEA3 family genes, Ccnd2, Crh, and Zic1. IHC analyses for both clinicopathologic and molecular genetic analyses indicate that mouse and human tumors showed that CCND2 and MUC5AC CDS is an independent disease entity from ES. Few ancillary are reliable biomarkers to distinguish CDS from ES. Gene silenc- markers have been used in the differential diagnosis of CDS, and ing of CIC-DUX4 as well as Ccnd2, Ret, and Bcl2 effectively additional CDS-specific biomarkers are needed for more defini- inhibited CDS tumor growth in vitro. The CDK4/6 inhibitor tive classification. Here, we report the generation of an ex vivo palbociclib and the soft tissue sarcoma drug trabectedin also mouse model for CDS by transducing embryonic mesenchymal blocked the growth of mouse CDS. In summary, our mouse cells (eMC) with human CIC-DUX4 cDNA. Recipient mice trans- model provides important biological information about CDS planted with eMC-expressing CIC-DUX4 rapidly developed an and provides a useful platform to explore biomarkers and ther- aggressive, undifferentiated sarcoma composed of small round to apeutic agents for CDS.
    [Show full text]
  • Quantitative Proteomics Reveals Changes Induced by TIMP-3 on Cell Membrane Composition and Novel Metalloprotease Substrates
    International Journal of Molecular Sciences Article Quantitative Proteomics Reveals Changes Induced by TIMP-3 on Cell Membrane Composition and Novel Metalloprotease Substrates Anna Paola Carreca 1,† , Veronica Maria Pravatà 2,3,† , Danilo D’Apolito 4,5 , Simone Bonelli 1, Matteo Calligaris 1,6, Elisa Monaca 7 , Stephan A. Müller 3, Stefan F. Lichtenthaler 3,8,9 and Simone Dario Scilabra 1,* 1 Proteomics Group of Fondazione Ri.MED, Department of Research IRCCS ISMETT, via Ernesto Tricomi 5, 90145 Palermo, Italy; [email protected] (A.P.C.); [email protected] (S.B.); [email protected] (M.C.) 2 Division of Gene Regulation and Expression, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK; [email protected] 3 German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen Strasse 17, 81377 Munich, Germany; [email protected] (S.A.M.); [email protected] (S.F.L.) 4 Unità di Medicina di Laboratorio e Biotecnologie Avanzate, IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Via E. Tricomi 5, 90127 Palermo, Italy; [email protected] 5 Unità Prodotti Cellulari (GMP), Fondazione Ri.MED c/o IRCCS-ISMETT, Via E. Tricomi 5, 90127 Palermo, Italy 6 Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy 7 Fondazione Ri.MED, 90133 Palermo, Italy; [email protected] Citation: Carreca, A.P.; Pravatà, V.M.; 8 Neuroproteomics, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany D’Apolito, D.; Bonelli, S.; Calligaris, 9 Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany M.; Monaca, E.; Müller, S.A.; * Correspondence: [email protected]; Tel.: +39-(0)91-219-2430 Lichtenthaler, S.F.; Scilabra, S.D.
    [Show full text]
  • Role of Cellular Prion Protein in Central Nervous System Myelination
    Scuola Internazionale Superiore di Studi Avanzati - SISSA Trieste, Italy ROLE OF CELLULAR PRION PROTEIN IN CENTRAL NERVOUS SYSTEM MYELINATION Thesis submitted for the degree of “Philosophiae Doctor” CANDIDATE SUPERVISORS Elisa Meneghetti Prof. Giuseppe Legname, Ph.D. Dr.Federico Benetti, Ph.D. Academic year 2014/2015 2 DECLARATION The work described in this thesis has been carried out at Scuola Internazionale Superiore di Studi Avanzati (SISSA), Trieste, Italy, from November 2011 to October 2015. During my Ph.D. course I contributed to two research articles: - Gasperini, L., E. Meneghetti, B. Pastore, F. Benetti and G. Legname (2015). "Prion Protein and Copper Cooperatively Protect Neurons by Modulating NMDA Receptor Through S-nitrosylation." Antioxidants & Redox Signaling 22(9): 772-784. Included in the “APPENDIX” section. - Gasperini, L., Meneghetti, E., Legname, G. and Benetti, F. “The Absence of the Cellular Prion Protein Impairs Copper Metabolism and Copper-Dependent Ferroxidase Activity, Thus Affecting Iron Mobilization.” To be submitted. 3 4 INDEX LIST OF ABBREVIATIONS .............................................................................................................. 7 ABSTRACT ............................................................................................................................................ 11 INTRODUCTION ............................................................................................................................... 13 PRION DISEASES ..............................................................................................................................
    [Show full text]